Introduction:
Evonik with an investment of US$220 million plans for the construction of new pharmaceutical lipid production facility. The new facility will be located in Indiana, United States.
Features:
The new facility is expected to provide industry with access to critical adjuvants needed for mRNA vaccines and other nucleic acid therapies.
The new flexible development and production facility enables rapid scale-up of a variety of speciality lipids to high quality standards to serve future applications of RNA technology in infectious disease control, cancer immunotherapy, protein replacement therapy and gene therapy.
The new lipid innovation centre aims to secure the health innovations of tomorrow. In addition, it supports the U.S. for pandemic preparation and enables for the development of cutting-edge medicines.
This global facility reinforces unique position as a CDMO for the pharmaceutical industry. This new world-scale facility helps in building a unique position as a CDMO in the pharmaceutical industry.
The construction of the new facility is expected to be completed and start its production in 2025.
Specifications:
| Name | Evonik |
| Type | New Construction |
| Budget | US$220 million |
| Year | 2025 |
